Successful apatinib treatment for advanced clear cell renal carcinoma as a first-line palliative treatment: A case report

BACKGROUND: Apatinib is an orally bioavailable small-molecule receptor tyrosine kinase inhibitor. In December 2014, the China Food and Drug Administration made it the first anti-angiogenic therapy to be approved for treating metastatic gastric cancer. It was specifically designated as a third-line o...

Descripción completa

Detalles Bibliográficos
Autores principales: Wei, Hang-Ping, Mao, Jie, Hu, Zu-Liang
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Baishideng Publishing Group Inc 2022
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9048545/
https://www.ncbi.nlm.nih.gov/pubmed/35582051
http://dx.doi.org/10.12998/wjcc.v10.i11.3593

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9048545/
https://www.ncbi.nlm.nih.gov/pubmed/35582051
http://dx.doi.org/10.12998/wjcc.v10.i11.3593

Ejemplares similares